- Medibank Private Revenue: Achieved A$4.27 billion in revenue for the first half of the year, closely aligning with the expected A$4.29 billion.
- Interim Dividend: Declared an interim dividend of A$0.0780 per share.
- Net Investment Income: Reported a net investment income of A$114.5 million.
- Analyst Ratings: Received 4 buy recommendations, 8 hold recommendations, and no sell recommendations from analysts.
A look at Medibank Private Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 4 | |
| Growth | 4 | |
| Resilience | 4 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Medibank Private, a company providing private health care coverage, seems to have a promising long-term outlook based on Smartkarma Smart Scores. With strong ratings in Dividend, Growth, Resilience, and Momentum, the company appears well-positioned for future success. This indicates that Medibank Private is likely to provide stable dividends, experience steady growth, demonstrate resilience in challenging times, and maintain positive momentum in the market.
Despite a moderate rating in Value, Medibank Private‘s overall outlook remains positive, suggesting that the company is viewed favorably across various key factors by Smartkarma Smart Scores. This optimistic assessment could bode well for investors looking for a consistent performer in the private health care sector in Australia.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
